APP and Alzheimer disease: To assess the role of low-circulating melatonin levels in AD-induced cardiac anomalies, mice with APP/PS1 mutations were supplemented with melatonin (20 mg/kg/day, p.o.)for 6 weeks37 prior to the assessment of cognitive function, cardiac geometry, and contractile function.